Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials
Purpose: To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME). Design: A post hoc analysis of the randomized, double-masked, noninferiority YOSEMITE/RHINE (NC...
Saved in:
| Main Authors: | Usha Chakravarthy, FRCOphth, PhD, Varun Chaudhary, MD, FRCS(C), Srinivas R. Sadda, MD, Colin S. Tan, FRCOphth, FRCSEd (Ophth), Stela Vujosevic, MD, PhD, Sascha Fauser, MD, Kara Gibson, PhD, Carl Glittenberg, MD, Nancy Holekamp, MD, FASRS, Ben Lanza, PhD, Andreas Maunz, PhD, Jeffrey R. Willis, MD, PhD, Rishi P. Singh, MD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Ophthalmology Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266691452500096X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison between Spectral-domain and Swept-source OCT Angiography Scans for the Measurement of Hyperreflective Foci in Age-related Macular Degeneration
by: Gissel Herrera, MD, et al.
Published: (2025-03-01) -
Optical Coherence Tomography Angiography Flow Signal in Non-Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab
by: Max Brinkmann, et al.
Published: (2025-02-01) -
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies
by: Yusuke Inoue, MD, PhD, et al.
Published: (2025-08-01) -
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L
by: Hideyuki Harada, MD, PhD, et al.
Published: (2025-06-01) -
Independent association of a 17q21 variant with exacerbations in type 2–low adult asthma
by: Yumi Ishiyama, MD, et al.
Published: (2025-08-01)